StockWire X
Get Free Alerts
StockWire X

Imugene Azer-cel Posts 77% Response in 56 Phase 1b Patients [VIDEO]

Video thumbnail
Imugene Ltd
Company Hub
Market Impact
5/10

Imugene azer-cel clinical progress now spans 140 treated patients, a 77% response rate in the later trial and a cost base cut by about 40%.

By Josua Ferreira -

Key Takeaways

  • Imugene has treated 140 patients with azer-cel, with a 77% response rate in 56 patients with B-cell cancers in the later trial.
  • The later trial reported no graft-versus-host disease and no severe immune reactions at the higher grades.
  • Early combination data for patients who stopped responding to older drugs shows 6 of 7 responding, a very small group the company calls early.
  • Key dates are December 2026 for new data, mid 2027 for a US regulator meeting and a final-stage study starting in the second half of 2027 or 2028.
  • The company has cut its cost base by about 40%, saved $4.2 million in pay costs and says licensing talks are underway.
This is a special feature video produced for our partner.
Topic Hubs
Biotech & Health Biotechnology Healthcare Regulation Life Sciences Pharmaceutical Research
Most Popular
Categories

You May Also Like

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

  • Breaking ASX announcements delivered within minutes
  • Alerts delivered with expert analysis
  • Optional text alert for subscribers
  • No spam policy, unsubscribe any time
News
ASX Stock News
ASX Videos
Trending Topics▾
Capital MarketsRenewable EnergyMedical ImagingPortfolio ManagementASX 200ForexInterest RatesAll OrdinariesInflationAll Hub Pages
Analysis
Education
Free Alerts

About the Publisher

StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.

Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.

Use of Technology

We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.

While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.

Feedback and Accuracy

We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Editorial Standards

Disclaimer

StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).

StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.

Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.

StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.

Disclosure

StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.

If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Disclaimer